Skip to content
L217L217L217

Drawing based on the label description. No photo yet.

“5 mg, white to off white, caplet-shaped tablets debossed with 'L217' on one side and plain on other side”

L217 pill

Pill with imprint L217 is white, capsule, 8 mm and has been identified as Lamotrigine Chewable Dispersible 5 mg. It is used for seizures. It is supplied by Alembic Pharmaceuticals Limited.

Lamotrigine Chewable Dispersible 5 mg

Imprint
L217
Strength
5 mg
Used for
Seizures
Color
White
Shape
Capsule / oblong
Size
8 mm
Score
No score line
Form
Tablet, for suspension
Manufacturer
Alembic Pharmaceuticals Limited
NDC
46708-095, 46708-095-30, 46708-095-91, 46708-095-31

Source: the official drug label on DailyMed (US National Library of Medicine). Last checked .

Report a mistake

Please do not include personal health information. For questions about your medicine, ask a pharmacist.

All Lamotrigine Chewable Dispersible pills and guides

What is Lamotrigine Chewable Dispersible used for?

Lamotrigine Chewable Dispersible is used for seizures.

Official uses from the US prescribing label

. Epilepsy

Adjunctive Therapy Lamotrigine tablets for oral suspension USP (chewable dispersible tablets) are indicated as adjunctive therapy for the following seizure types in patients aged 2 years and older:

  • partial-onset seizures.
  • primary generalized tonic-clonic (PGTC) seizures.
  • generalized seizures of Lennox-Gastaut syndrome.

Monotherapy Lamotrigine tablets for oral suspension USP (chewable dispersible tablets) are indicated for conversion to monotherapy in adults (aged 16 years and older) with partial-onset seizures who are receiving treatment with carbamazepine, phenytoin, phenobarbital, primidone, or valproate as the single antiepileptic drug (AED). Safety and effectiveness of lamotrigine tablets for oral suspension USP (chewable dispersible tablets)have not been established as initial monotherapy; for conversion to monotherapy from AEDs other than carbamazepine, phenytoin, phenobarbital, primidone, or valproate; or for simultaneous conversion to monotherapy from 2 or more concomitant AEDs.

. Bipolar Disorder

Lamotrigine tablets for oral suspension USP (chewable dispersible tablets) are indicated for the maintenance treatment of bipolar I disorder to delay the time to occurrence of mood episodes (depression, mania, hypomania, mixed episodes) in patients treated for acute mood episodes with standard therapy.

Limitations of Use

Treatment of acute manic or mixed episodes is not recommended. Effectiveness of lamotrigine tablets for oral suspension USP (chewable dispersible tablets) in the acute treatment of mood episodes has not been established.

From the FDA-approved label on DailyMed (published Jan 19, 2023).

Doctors sometimes prescribe a medicine for other reasons too. If you are not sure what yours is for, ask your pharmacist.

Is this your pill? Check every detail

  • One side shows L217 and the other side is plain.
  • It is white, capsule, 8 mm.
  • Its score line and coating match the details on this page.
  • It came from a pharmacy package that names the same drug.

Sold under the brand name Lamotrigine.

Ingredients

Active: Lamotrigine

Inactive: Mannitol, Crospovidone (120 .mu.m), Povidone K30, Microcrystalline Cellulose, Aspartame, Silicon Dioxide, Magnesium Stearate, Talc, Blackberry

Other pills with imprint L217

Same imprint, different listing. Check the color, size and maker against your pill.

Pills that look similar but are different drugs

Same color and shape, different medicine. This is why the imprint matters.

Other Lamotrigine Chewable Dispersible pills